FDA Approves DAPAGLIFLOZIN — Florida Pharmaceutical Products, LLC

# FDA Approves Generic Dapagliflozin from Florida Pharmaceutical Products The FDA has approved Florida Pharmaceutical Products, LLC's generic formulation of dapagliflozin (ANDA211156), a widely-used SGLT2 inhibitor for diabetes and heart failure, potentially intensifying competition in the multi-billion dollar dapagliflozin market and exerting downward pricing pressure on both generic and branded versions. The approval could accelerate market consolidation among generic manufacturers while expanding patient access to this therapeutically important drug class.